Poolbeg Pharma Dosed Eight Patients in Cancer Trial
The company reached a milestone in its clinical study testing a therapy for Cytokine Release Syndrome.
Updated on Sept. 28, 2026 in Biotech
Live Poll
Do you trust that current pharmaceutical clinical trial processes adequately prioritize patient safety?
Poolbeg Pharma has successfully dosed eight participants in its POLB 001 TOPICAL clinical trial. The study evaluates the preventative treatment for Cytokine Release Syndrome in patients receiving the bispecific antibody teclistamab.
Why it matters
The trial aims to address the dangerous side effects associated with cancer treatments like teclistamab in multiple myeloma patients. Finding a preventative therapy could significantly improve outcomes for those undergoing complex immunotherapy.
The clinical trial is testing POLB 001, a therapeutic candidate designed to mitigate Cytokine Release Syndrome. Researchers are currently utilizing a six-patient safety cohort as part of the broader 30-participant recruitment goal.
The players
Poolbeg Pharma
Poolbeg Pharma is a clinical-stage biopharmaceutical company focused on developing new therapies for infectious diseases and immune-related conditions.
The details
The trial focuses on multiple myeloma patients treated with teclistamab, a bispecific antibody therapy. Additional clinical sites are currently expressing interest in joining the study to support expansion efforts.
Timeline
The first patient was dosed in July 2026.
Poolbeg Pharma released a recruitment update on September 28, 2026.
The Tech Race
The study represents a strategic effort to manage the inflammatory complications that often limit the efficacy of modern immunotherapy drugs. By targeting these immune responses, the company aims to establish a new standard of care in the competitive oncology pipeline.
Successful trial results could eventually lower the risk of severe inflammatory reactions for cancer patients receiving immunotherapy. This development offers potential for safer treatment protocols and reduced hospital stays during complex cancer care.
The takeaway
This trial highlights the ongoing effort to minimize the side effects of intensive immune-based cancer treatments. Developing preventative therapies is a critical step in making high-potency antibody treatments more manageable for patients.
Further reading
Learn more about the latest breakthroughs in the industry on our Biotech page.
Live Poll
Do you trust that current pharmaceutical clinical trial processes adequately prioritize patient safety?
